Based on the provided forecast data, the sales value for Genito Urinary System and Sex Hormones in Canada remains relatively stable from 2024 to 2028, showing no significant variation. The year-on-year variation for each year from 2024 to 2028 is as follows: 0.00%, -0.84%, 0.00%, and 0.00%. The Compound Annual Growth Rate (CAGR) from 2024 to 2028 is approximately -0.17%.
Future trends to watch in Genito Urinary System and Sex Hormones Sales in Canada could include potential developments in drug innovations, demographic changes, and enhanced healthcare policies that may positively influence the market growth. Monitoring the regulatory landscape and competitive dynamics will also be crucial in understanding future market directions.
